Alethia Young


Credit Suisse Cuts Price Target for Gilead Sciences, Inc. (GILD) on Back of Low Visibility on HCV

Gilead Sciences, Inc. (NASDAQ:GILD) shares have dipped 22% this past year, as investors are skeptical as to whether the biotech giant’s HCV franchise …

Credit Suisse Highlights The Million Dollar Question For Biogen Inc (BIIB)

Credit Suisse analyst Alethia Young posits, “To acquire or to be acquired, that is the question for Biogen Inc (NASDAQ:BIIB).” Until an answer …

Credit Suisse Dives In on Gilead Sciences, Inc. (GILD) as Relationship with Express Scripts in HCV Is Potentially Improving

Analyst Alethia Young from Credit Suisse gave her thoughts on Gilead Sciences, Inc. (NASDAQ:GILD) and its place in HCV.

Deutsche Bank Maintains Buy On Intercept On The Back Of FDA Breakthrough Designation Status

In a research report released Friday, Deutsche Bank analyst Alethia Young maintained a Buy rating on Intercept Pharma (NASDAQ:ICPT) with a price target …

Deutsche Bank Sees Short And Long Term Upside In Regulus’ Pipeline Assets

In a research report released Monday, Deutsche Bank analyst Alethia Young maintained a Buy rating on Regulus Therapeutics (NASDAQ:RGLS) with a $30 price target, …

Deutsche Bank Maintains Buy On Avanir Pharmaceuticals Following CTAD Conference

In a research note issued today, Deutsche Bank analyst Alethia Young maintained a Buy rating on Avanir Pharmaceuticals (NASDAQ:AVNR) with a $17 price target, following numerous presentations of …

Deutsche Bank Initiates Buy On Avanir Pharmaceuticals; Sees 27% Upside For The Stock

In a research report sent to investors today, Deutsche Bank analyst Alethia Young initiated coverage on Avanir Pharmaceuticals (NASDAQ:AVNR) with a Buy rating and a $17 price …

Deutsche Bank Reiterates Buy On Intercept Pharmaceuticals, $500 PT

In a research report issued today, Deutsche Bank analyst Alethia Young reiterated a Buy rating on Intercept Pharmaceuticals Inc (NASDAQ:ICPT) with a price target …